Zymeworks (ZYME) said Monday that new preclinical data for its experimental respiratory inflammation drug ZW1528 has shown positive results.
The drug targets two proteins involved in inflammation and blocks their signals to reduce immune responses, the company said.
In lab studies, ZW1528 worked well at stopping inflammation in immune cells taken from chronic obstructive pulmonary disease patients and also showed strong results in animal tests involving lung inflammation caused by dust mites, it added.
The drug remained stable at high concentrations, supporting the option of administering it through subcutaneous injection, according to the company.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。